Back to results
US 12,577,307 B2Granted
Method and medicament for treating cancer unresponsive to PD-1/PD-L1 signaling inhibitor
AssigneeGenentech, Inc.
InventorsNobuyuki Ishikura, Toshiki Iwai, Masamichi Sugimoto
Life of this patent
Estimating the term…
Abstract
The present invention relates to medicaments, treatment methods, kits, and uses for treating cancer in individuals, characterized in that a VEGF signaling inhibitor and a PD-1/PD-L1 signaling inhibitor are administered in combination, as well as VEGF signaling inhibitors, PD-1/PD-L1 signaling inhibitors, and combinations thereof.
Claims8
A method of treating cancer resistant to a PD-1/PD-L1 signaling inhibitor in an individual, wherein the method comprises
- examining the individual for the presence or absence of resistance to a PD-1/PD-L1 signaling inhibitor,
- selecting the individual for treatment based upon the determination that the individual has cancer resistant to a PD-1/PD-L1 signaling inhibitor, and
- administering bevacizumab and MPDL3280A to the individual.
Dependencies are inferred from the claim text.